Schroder Investment Management Group,
Trexquant Investment LP,
DF Dent & Co. Inc, and
Headlands Technologies LLC have increased their stake in
Zoetis Inc. (NYSE:ZTS), while
Boston Family Office LLC and
Alliancebernstein L.P. reduced their holdings. Despite Q4 earnings, the ZTS stock declined but is still considered a compelling opportunity by some for long-term growth.
Allstate Corp,
Arrowstreet Capital Limited Partnership, and
Geode Capital Management LLC have recently
purchased Zoetis' shares, amidst others lowering their stock position, including
Groupama Asset Managment and the
California Public Employees Retirement System. Analysts speculate on Zoetis' performance post Q4 earnings results, with anticipation of continued earnings growth. Zoetis saw substantial
growth in revenue during Q4 2024 despite the fall in stocks. The pharma giant recently became the focus of attention with the conditional approval from the USDA for its
Avian Influenza Vaccine, marking another crucial step towards innovation and leading to increased profitability in the pharmaceutical sector.
Zoetis ZTS News Analytics from Mon, 04 Nov 2024 08:00:00 GMT to Sat, 05 Apr 2025 22:42:00 GMT -
Rating -1
- Innovation 3
- Information 2
- Rumor 2
